bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S3 from Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression
Authors: Keysar Stephen B. , Eagles Justin R. , Miller Bettina , Jackson Brian C. , Chowdhury Farshad N. , Reisinger Julie , Chimed Tugs-Saikhan , Le Phuong N. , Morton John J. , Somerset Hilary L. , Varella-Garcia Marileila , Tan Aik-Choon , Song John I. , Bowles Daniel W. , Reyland Mary E. , Jimeno Antonio
Published: April 2023

Fig. S3. Patient vs. PDX gene expression correlation. (A) Hierarchical clustering of 2 ACC (CUSG004, -005) and 1 MEC (CUSG006) PDX cases over multiple generations. (B) Gene expression was log2 normalized and R2 statistics were calculated for patient vs. F1 (Left Column) and patient vs. F2 (Right Column). We observed a minor decrease in the percent variance explained, R2, in the F2 vs. F0 when compared to the F1 vs. F0. The bootstrapped 95% confidence intervals for the CUSG005 and CUSG006 indicate that these R2 values are significantly different that is possibly due to a small degree of drift in gene expression through passaging. (C and D) Heatmaps displaying differentially expressed genes between F1 and F2 PDX generations. Genes were filtered for FDR adjusted p-value < 0.10 and logFC > 2. (E) There is an 85% overlap between genes that significantly change between the F0 and F1/F2 generations. No significantly differentially expressed genes were identified when comparing F2 vs. F1 samples.
permission letter from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Authors: Wu Hong-Wei , Sheard Michael A. , Malvar Jemily , Fernandez G. Esteban , DeClerck Yves A. , Blavier Laurence , Shimada Hiroyuki , Theuer Charles P. , Sposto Richard , Seeger Robert C.
Published: April 2023

Permission letter regarding inclusion of information of CHLA-255 C-Myc over-expression
Appendix figures from Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study
Authors: Kim Edward S. , Kelly Karen , Paz-Ares Luis G. , Garrido Pilar , Jalal Shadia , Mahadevan Daruka , Gutierrez Martin , Provencio Mariano , Schaefer Eric , Shaheen Monte , Johnston Erica L. , Turner P. Kellie , Kambhampati Siva Rama Prasad , Beckmann Richard , Hossain Anwar , John William J. , Goldman Jonathan W.
Published: April 2023

Third part of the appendix
Supplementary Fig. 1-8 from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Authors: Wu Hong-Wei , Sheard Michael A. , Malvar Jemily , Fernandez G. Esteban , DeClerck Yves A. , Blavier Laurence , Shimada Hiroyuki , Theuer Charles P. , Sposto Richard , Seeger Robert C.
Published: April 2023

Targeting CD105+ Microenvironment cells enhances immunotherpy of Dinutuxmab with aNK cells against neuroblastoma
Supplementary Figure S3 from Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas)
Authors: Sanfilippo Roberta , Jones Robin L. , Blay Jean-Yves , Le Cesne Axel , Provenzano Salvatore , Antoniou Georgios , Mir Olivier , Fucà Giovanni , Fumagalli Elena , Bertulli Rossella , Stacchiotti Silvia , Brahmi Mehdi , Grosso Federica , Dufresne Armelle , Hindi Nadia , Sbaraglia Marta , Gronchi Alessandro , Collini Paola , Dei Tos Angelo P. , Casali Paolo G.
Published: April 2023

Supplementary Figure S3. Kaplan-Meier curves for progression-free survival of patients treated with mTOR inhibitors according to the primary tumor site. Blue line indicates patients with uterine PEComa while yellow line indicates patients with extra-uterine PEComa.
Supplementary Table S3 from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
Authors: González-González Adrián , Muñoz-Muela Esperanza , Marchal Juan A. , Cara Francisca E. , Molina Maria P. , Cruz-Lozano Marina , Jiménez Gema , Verma Akanksha , Ramírez Alberto , Qian Wei , Chen Wen , Kozielski Anthony J. , Elemento Olivier , Martín-Salvago María D. , Luque Rafael J. , Rosa-Garrido Carmen , Landeira David , Quintana-Romero María , Rosato Roberto R. , García Maria A. , Ramirez-Tortosa Cesar L. , Kim Hanna , Rodriguez-Aguayo Cristian , Lopez-Berestein Gabriel , Sood Anil K. , Lorente Jose A. , Sánchez-Rovira Pedro , Chang Jenny C. , Granados-Principal Sergio
Published: April 2023

Supplementary Table S3. Relapse-free survival of gene signature and single genes according to intrinsic subtype.
Supplementary Figure S1 from Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas)
Authors: Sanfilippo Roberta , Jones Robin L. , Blay Jean-Yves , Le Cesne Axel , Provenzano Salvatore , Antoniou Georgios , Mir Olivier , Fucà Giovanni , Fumagalli Elena , Bertulli Rossella , Stacchiotti Silvia , Brahmi Mehdi , Grosso Federica , Dufresne Armelle , Hindi Nadia , Sbaraglia Marta , Gronchi Alessandro , Collini Paola , Dei Tos Angelo P. , Casali Paolo G.
Published: April 2023

Complicated abdominal tissue response to pazopanib as fourth-line therapy in a woman with uterine PEComa. Panel A shows the baseline CT scan; panel B shows the complicated tissue response after 1 month of treatment.
Supplementary Table S2 from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
Authors: González-González Adrián , Muñoz-Muela Esperanza , Marchal Juan A. , Cara Francisca E. , Molina Maria P. , Cruz-Lozano Marina , Jiménez Gema , Verma Akanksha , Ramírez Alberto , Qian Wei , Chen Wen , Kozielski Anthony J. , Elemento Olivier , Martín-Salvago María D. , Luque Rafael J. , Rosa-Garrido Carmen , Landeira David , Quintana-Romero María , Rosato Roberto R. , García Maria A. , Ramirez-Tortosa Cesar L. , Kim Hanna , Rodriguez-Aguayo Cristian , Lopez-Berestein Gabriel , Sood Anil K. , Lorente Jose A. , Sánchez-Rovira Pedro , Chang Jenny C. , Granados-Principal Sergio
Published: April 2023

Supplementary Table S2. Relapse-free survival of gene signature and single genes according to hormone status.
Supplementary Figure S2 from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
Authors: González-González Adrián , Muñoz-Muela Esperanza , Marchal Juan A. , Cara Francisca E. , Molina Maria P. , Cruz-Lozano Marina , Jiménez Gema , Verma Akanksha , Ramírez Alberto , Qian Wei , Chen Wen , Kozielski Anthony J. , Elemento Olivier , Martín-Salvago María D. , Luque Rafael J. , Rosa-Garrido Carmen , Landeira David , Quintana-Romero María , Rosato Roberto R. , García Maria A. , Ramirez-Tortosa Cesar L. , Kim Hanna , Rodriguez-Aguayo Cristian , Lopez-Berestein Gabriel , Sood Anil K. , Lorente Jose A. , Sánchez-Rovira Pedro , Chang Jenny C. , Granados-Principal Sergio
Published: April 2023

Supplementary Figure 2. Target efficiency of ATF4-siRNA, effects of ATF4 knockdown on tumor cell migration, and ATF4 expression in mammospheres.
Supplementary Tables from Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer
Authors: Huang Hai , Wang Chao , Liu Fei , Li Hui-Zhen , Peng Guang , Gao Xu , Dong Ke-Qin , Wang Hong-Ru , Kong De-Pei , Qu Min , Dai Li-He , Wang Kai-Jian , Zhou Zhe , Yang Jun , Yang Ze-Yu , Cheng Yan-Qiong , Tian Qin-Qin , Liu Dan , Xu Chuan-Liang , Xu Dan-Feng , Cui Xin-Gang , Sun Ying-Hao
Published: April 2023

Supplementary Tables
Supplementary Figures and Figure Legends from Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer
Authors: Huang Hai , Wang Chao , Liu Fei , Li Hui-Zhen , Peng Guang , Gao Xu , Dong Ke-Qin , Wang Hong-Ru , Kong De-Pei , Qu Min , Dai Li-He , Wang Kai-Jian , Zhou Zhe , Yang Jun , Yang Ze-Yu , Cheng Yan-Qiong , Tian Qin-Qin , Liu Dan , Xu Chuan-Liang , Xu Dan-Feng , Cui Xin-Gang , Sun Ying-Hao
Published: April 2023

Supplementary Figures and Figure Legends
Table S3 from Machine Learning to Build and Validate a Model for Radiation Pneumonitis Prediction in Patients with Non–Small Cell Lung Cancer
Authors: Yu Hao , Wu Huanmei , Wang Weili , Jolly Shruti , Jin Jian-Yue , Hu Chen , Kong Feng-Ming (Spring)
Published: April 2023

prediction abilities in the previous reports
Supplementary Figure 2 from A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma
Authors: Ramaswami Ramya , Uldrick Thomas S. , Polizzotto Mark N. , Wyvill Kathleen M. , Goncalves Priscila , Widell Anaida , Lurain Kathryn , Steinberg Seth M. , Figg William Douglas , Tosato Giovanna , Whitby Denise , Yarchoan Robert
Published: April 2023

Kaplan-Meier curve of duration of response among 9 responders on the study, measured from the date of response (as compared with baseline) till progression or censorship when patient follow-up ended. Median time to progression was not reached. Hatch marks denote time that patients are censored.
Supplementary Data from A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
Authors: Berenson James R. , To Jennifer , Spektor Tanya M. , Martinez Daisy , Turner Carley , Sanchez Armando , Ghermezi Matthew , Eades Benjamin M. , Swift Regina A. , Schwartz Gary , Eshaghian Shahrooz , Stampleman Laura , Moss Robert A. , Lim Stephen , Vescio Robert
Published: April 2023

Supplementary Tables and Figure
Supplementary Table2 from Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Authors: Gui Yirui , Aguilar-Mahecha Adriana , Krzemien Urszula , Hosein Abdel , Buchanan Marguerite , Lafleur Josiane , Pollak Michael , Ferrario Cristiano , Basik Mark
Published: April 2023

Supplementary Table2 shows Top 10 up regulated genes in metastatic CAFs
Figure S7 from Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas
Authors: Jiang Hong , Shin Dong Ho , Nguyen Teresa T. , Fueyo Juan , Fan Xuejun , Henry Verlene , Carrillo Caroline C. , Yi Yanhua , Alonso Marta M. , Collier Tiara L. , Yuan Ying , Lang Frederick F. , Gomez-Manzano Candelaria
Published: April 2023

PD-L1 expression on mouse melanoma cells. A, PD-L1 expression in mouse melanoma B16F10 Red-FLuc cells. Cells were mock-infected with PBS or infected with Delta-24-RGDOX (D24-RGDOX, 100 PFU/cell) in the presence or absence of mouse IFNÎ³ (50 U/ml) for 48 hours and then analyzed with flow cytometry for PD-L1 expression. B, PD-L1 expression in melanoma cells from implanted tumors. After the implantation of B16F10 cells expressing enhanced green-fluorescent protein (EGFP), Delta-24-RGDOX (D24-RGDOX) was injected intratumorally on days 7. After 48 hours, the tumors (taken from 3-4 mice/group) were harvested, dissociated, and analyzed with flow cytometry for PD-L1 expression. Tumor cells were gated for EGFP+. IgG staining was used as a negative control.
Supplementary Table1 from Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Authors: Gui Yirui , Aguilar-Mahecha Adriana , Krzemien Urszula , Hosein Abdel , Buchanan Marguerite , Lafleur Josiane , Pollak Michael , Ferrario Cristiano , Basik Mark
Published: April 2023

Supplementary Table1 Clinical information of tumors from which used CAFs isolated
Supplementary Figure Legend from Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Authors: Gui Yirui , Aguilar-Mahecha Adriana , Krzemien Urszula , Hosein Abdel , Buchanan Marguerite , Lafleur Josiane , Pollak Michael , Ferrario Cristiano , Basik Mark
Published: April 2023

Figure S1-S8 legend
Figure S5 from Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas
Authors: Jiang Hong , Shin Dong Ho , Nguyen Teresa T. , Fueyo Juan , Fan Xuejun , Henry Verlene , Carrillo Caroline C. , Yi Yanhua , Alonso Marta M. , Collier Tiara L. , Yuan Ying , Lang Frederick F. , Gomez-Manzano Candelaria
Published: April 2023

Effector T cells frequency in CD8+ and CD4+ T cells. Tumors were implanted and treated as depicted in Fig. 2A. Three days after the last viral injection, lymphocytes from spleens or inguinal lymph nodes (TDLN, 4 to 5 mice/group) were analyzed with flow cytometry. Values represent the mean {plus minus} standard deviation (n = 3). * P < 0.05, 2-tailed Student t test. D24-RGDOX: Delta-24-RGDOX.
Figure S5 from Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Authors: Gui Yirui , Aguilar-Mahecha Adriana , Krzemien Urszula , Hosein Abdel , Buchanan Marguerite , Lafleur Josiane , Pollak Michael , Ferrario Cristiano , Basik Mark
Published: April 2023

Figure S5 shows mRNA expression of pdgfa in different mCAFs.
Figure S2 from Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas
Authors: Jiang Hong , Shin Dong Ho , Nguyen Teresa T. , Fueyo Juan , Fan Xuejun , Henry Verlene , Carrillo Caroline C. , Yi Yanhua , Alonso Marta M. , Collier Tiara L. , Yuan Ying , Lang Frederick F. , Gomez-Manzano Candelaria
Published: April 2023

A, Quantification of the tumor bioluminescence in the mice from the indicated treatment groups. D24-RGDOX: Delta-24-RGDOX. B, Waterfall plots showing tumor burden change from baseline in mice of indicated treatment groups base on the bioluminescence from the tumor. Baseline time point: Day 6. Evaluation time point: Day 39 or the last time point before euthanasia.
Supplementary Figure 5 from The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
Authors: Marzi Laetitia , Szabova Ludmila , Gordon Melanie , Weaver Ohler Zoe , Sharan Shyam K. , Beshiri Michael L. , Etemadi Moudjib , Murai Junko , Kelly Kathleen , Pommier Yves
Published: April 2023

Topotecan and the indenoisoquinolines TOP1 inhibitors are correlated with response to talazoparib and olaparib in the NCI-60 (panels A-D) and LMP744 is correlated with talazoparib (E), olaparib (F) and cisplatin (G) in the GDSC (MGH-Sanger) cell line panels. However, TOP1 inhibitors remain highly active in many cell lines (colored circles) that do not respond to olaparib, talazoparib or cisplatin. The red lines show the regression lines. The cell lines above the lines (upper left corners) are resistant to the PARP inhibitors but respond to the TOP1 inhibitors. LMP compounds are listed by their NSC numbers in the NCI-60 panels A-D (LMP400 = NSC724998; LMP744 = NSC706744 and LMP776 = NSC725776). LMP744 is also referred as MJ-III-65 in the GDSC (MGH-Sanger) database (panels E-G). Individual plots are snapshots from CellMinerCDB; https://discover.nci.nih.gov/cellminercdb).
Supplementary Figure 4 from The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
Authors: Marzi Laetitia , Szabova Ludmila , Gordon Melanie , Weaver Ohler Zoe , Sharan Shyam K. , Beshiri Michael L. , Etemadi Moudjib , Murai Junko , Kelly Kathleen , Pommier Yves
Published: April 2023

Antitumor activity and toxicity of the indenoisoquinolines LMP400, LMP744 and LMP776 in Brca1-deficient murine orthotopic allograft model for ovarian cancer and synergy of LMP400 with olaparib. A-C. Antitumor activity of LMP400, LMP744, LMP776, olaparib alone and olaparib combination with LMP400 represented as tumor volume changes in individual mice. Single treatment experiment (A) and Combination study (C). B-D. Mice Body Weight changes for the corresponding experiments. Single treatment experiment (B) and Combination study (D).
Supplementary Figure 2 from The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
Authors: Marzi Laetitia , Szabova Ludmila , Gordon Melanie , Weaver Ohler Zoe , Sharan Shyam K. , Beshiri Michael L. , Etemadi Moudjib , Murai Junko , Kelly Kathleen , Pommier Yves
Published: April 2023

CellMinerCDB snapshots (http://discover.nci.nih.gov/cellminercdb) demonstrating the correlations between the activity of the three clinical indenoisoquinolines and topotecan activity.
Supplementary figure 4 from Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning
Authors: Yokoyama Seiya , Hamada Taiji , Higashi Michiyo , Matsuo Kei , Maemura Kosei , Kurahara Hiroshi , Horinouchi Michiko , Hiraki Tsubasa , Sugimoto Tomoyuki , Akahane Toshiaki , Yonezawa Suguru , Kornmann Marko , Batra Surinder K. , Hollingsworth Michael A. , Tanimoto Akihide
Published: April 2023

Prognosis prediction by machine learning classifier in the k-fold CV test. Cox proportional hazard regression analysis for the comparison between the positive and negative groups selected by each classifier. Red solid line: predicted high-risk group (positive), blue line: other groups (negative). (A) 3-fold cross-validation test. (B) 4-fold cross-validation test. The insets show p-value (p) and hazard ratio (HR) of each test.
Supplementary figure 2 from Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning
Authors: Yokoyama Seiya , Hamada Taiji , Higashi Michiyo , Matsuo Kei , Maemura Kosei , Kurahara Hiroshi , Horinouchi Michiko , Hiraki Tsubasa , Sugimoto Tomoyuki , Akahane Toshiaki , Yonezawa Suguru , Kornmann Marko , Batra Surinder K. , Hollingsworth Michael A. , Tanimoto Akihide
Published: April 2023

Difference in the expression level of mucins between Cluster 1 and other clusters selected by cluster analysis of the methylation status of mucin genes MUC1, MUC2, and MUC4. Expression levels show relative quantification (log10).
Supplementary Material and Methods from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Authors: de Jonge Marthe M. , Ritterhouse Lauren L. , de Kroon Cornelis D. , Vreeswijk Maaike P.G. , Segal Jeremy P. , Puranik Rutika , Hollema Harry , Rookus Matti A. , van Asperen Christi J. , van Leeuwen Flora E. , Smit Vincent T.H.B.M. , Howitt Brooke E. , Bosse Tjalling
Published: April 2023

Supplementary Material and Methods
Supplementary Figures from High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Authors: Benayed Ryma , Offin Michael , Mullaney Kerry , Sukhadia Purvil , Rios Kelly , Desmeules Patrice , Ptashkin Ryan , Won Helen , Chang Jason , Halpenny Darragh , Schram Alison M. , Rudin Charles M. , Hyman David M. , Arcila Maria E. , Berger Michael F. , Zehir Ahmet , Kris Mark G. , Drilon Alexander , Ladanyi Marc
Published: April 2023

Supplementary Figure1. ROS1 Intron 31 coverage by DNASeq. Supplementary Figure 2. Access to adequate material for RNA extraction.
Supplementary Fig. S4 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Authors: de Jonge Marthe M. , Ritterhouse Lauren L. , de Kroon Cornelis D. , Vreeswijk Maaike P.G. , Segal Jeremy P. , Puranik Rutika , Hollema Harry , Rookus Matti A. , van Asperen Christi J. , van Leeuwen Flora E. , Smit Vincent T.H.B.M. , Howitt Brooke E. , Bosse Tjalling
Published: April 2023

CD8-positive T-cell infiltrate stratified by loss of heterozygosity status.
Supplementary Fig. S2 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Authors: de Jonge Marthe M. , Ritterhouse Lauren L. , de Kroon Cornelis D. , Vreeswijk Maaike P.G. , Segal Jeremy P. , Puranik Rutika , Hollema Harry , Rookus Matti A. , van Asperen Christi J. , van Leeuwen Flora E. , Smit Vincent T.H.B.M. , Howitt Brooke E. , Bosse Tjalling
Published: April 2023

Overall survival of women with gBRCA/LOHpos ECs (n=24) and gBRCA/LOHneg ECs (n=16).
Supplementary Figure 2 from A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization
Authors: Hashimoto Yuuri , Koyama Kumiko , Kamai Yasuki , Hirotani Kenji , Ogitani Yusuke , Zembutsu Akiko , Abe Manabu , Kaneda Yuki , Maeda Naoyuki , Shiose Yoshinobu , Iguchi Takuma , Ishizaka Tomomichi , Karibe Tsuyoshi , Hayakawa Ichiro , Morita Koji , Nakada Takashi , Nomura Taisei , Wakita Kenichi , Kagari Takashi , Abe Yuki , Murakami Masato , Ueno Suguru , Agatsuma Toshinori
Published: April 2023

Growth inhibition activity in 8 cell lines with different HER3 expression levels
Supplementary Figure 1 from Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
Authors: Clark Amy S. , McAndrew Nicholas P. , Troxel Andrea , Feldman Michael , Lal Priti , Rosen Mark , Burrell Jessica , Redlinger Colleen , Gallagher Maryann , Bradbury Angela R. , Domchek Susan M. , Fox Kevin R. , O'Dwyer Peter J. , DeMichele Angela M.
Published: April 2023

Dose Cohort Scema
Supplementary Tables from Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial
Authors: Cox M. Christina , Castiello Luciano , Mattei Mauro , Santodonato Laura , D'Agostino Giuseppina , Muraro Elena , Martorelli Debora , Lapenta Caterina , Di Napoli Arianna , Di Landro Francesca , Cangemi Michela , Pavan Antonio , Castaldo Paolo , Hohaus Stefan , Donati Simona , Montefiore Enrica , Berdini Cinzia , Carlei Davide , Monque Domenica M. , Ruco Luigi , Prosperi Daniela , Tafuri Agostino , Spadaro Francesca , Sestili Paola , Spada Massimo , Dolcetti Riccardo , Santini Stefano M. , Rozera Carmela , Aricò Eleonora , Capone Imerio , Belardelli Filippo
Published: April 2023

Supplementary Table I: IFN-DC release criteria and median values registered among patient-derived IFN-DC (min-max range); Supplementary Table 2: Patients MHC-I and MHC-II alleles and IGHV epitope sequences
Figure S3 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
Authors: Costa-Nunes Carla , Cachot Amélie , Bobisse Sara , Arnaud Marion , Genolet Raphael , Baumgaertner Petra , Speiser Daniel E. , Sousa Alves Pedro M. , Sandoval Federico , Adotévi Olivier , Reith Walter , Protti Maria Pia , Coukos George , Harari Alexandre , Romero Pedro , Jandus Camilla
Published: April 2023

Supplementary Figure 3
Supplementary Data from Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials
Authors: Mir Olivier , Touati Nathan , Lia Michela , Litière Saskia , Le Cesne Axel , Sleijfer Stefan , Blay Jean-Yves , Leahy Michael , Young Robin , Mathijssen Ron H.J. , Van Erp Nielka P. , Gelderblom Hans , Van der Graaf Winette T. , Gronchi Alessandro
Published: April 2023

Supplementary Tables 1-4 and supplementary Figure 1
Table S 1-6 and Figures S1-3 from Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221
Authors: Tinker Anna V. , Hirte Holger W. , Provencher Diane , Butler Marcus , Ritter Heather , Tu Dongsheng , Azim Hatem A. , Paralejas Paulo , Grenier Nathalie , Hahn Shirley-Ann , Ramsahai Janelle , Seymour Lesley
Published: April 2023

Correlative studies and additional data as requested by reviewers
Supplementary Figure S6 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Authors: Gray Jhanelle E. , Saltos Andreas , Tanvetyanon Tawee , Haura Eric B. , Creelan Ben , Antonia Scott J. , Shafique Michael , Zheng Hong , Dai Wenjie , Saller James J. , Chen Zhihua , Tchekmedyian Nishan , Goas Kristen , Thapa Ram , Boyle Theresa A. , Chen Dung-Tsa , Beg Amer A.
Published: April 2023

Treatment impact on gene expression determined by volcano plots of RNA-seq data.
Supplementary Figure S5 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Authors: Gray Jhanelle E. , Saltos Andreas , Tanvetyanon Tawee , Haura Eric B. , Creelan Ben , Antonia Scott J. , Shafique Michael , Zheng Hong , Dai Wenjie , Saller James J. , Chen Zhihua , Tchekmedyian Nishan , Goas Kristen , Thapa Ram , Boyle Theresa A. , Chen Dung-Tsa , Beg Amer A.
Published: April 2023

CD33 staining of patient biopsies.
Supplementary Figure S3 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Authors: Gray Jhanelle E. , Saltos Andreas , Tanvetyanon Tawee , Haura Eric B. , Creelan Ben , Antonia Scott J. , Shafique Michael , Zheng Hong , Dai Wenjie , Saller James J. , Chen Zhihua , Tchekmedyian Nishan , Goas Kristen , Thapa Ram , Boyle Theresa A. , Chen Dung-Tsa , Beg Amer A.
Published: April 2023

Percentage of granulocytic (PMN) and monocytic MDSC in total PBMC of NSCLC trial participants.
Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Authors: Gray Jhanelle E. , Saltos Andreas , Tanvetyanon Tawee , Haura Eric B. , Creelan Ben , Antonia Scott J. , Shafique Michael , Zheng Hong , Dai Wenjie , Saller James J. , Chen Zhihua , Tchekmedyian Nishan , Goas Kristen , Thapa Ram , Boyle Theresa A. , Chen Dung-Tsa , Beg Amer A.
Published: April 2023

Approach to assess levels of monocytic and PMN MDSC in patient PBMCs.
Supplementary Figures from EPB41L5 Mediates TGFβ-Induced Metastasis of Gastric Cancer
Authors: Jeong Mi-Hyeon , Park Soo-Yeon , Lee Seung-Hyun , Seo JaeSung , Yoo Jung-Yoon , Park Seung-Ho , Kim Mi Jeong , Lee SooYeon , Jang Subhin , Choi Hyo-Kyoung , Lee Jae Eun , Shin Su-Jin , Choi Kyung-Chul , Cheong Jae-Ho , Yoon Ho-Geun
Published: April 2023

Supplementary Data_Tracked Changes
Supplementary Tables 4 and 5 from Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma
Authors: Lucas Fabienne , Rogers Kerry A. , Harrington Bonnie K. , Pan Alexander , Yu Lianbo , Breitbach Justin , Bundschuh Ralf , Goettl Virginia M. , Hing Zachary A. , Kanga Parviz , Mantel Rose , Sampath Deepa , Smith Lisa L. , Wasmuth Ronni , White Danielle K. , Yan Pearlly , Byrd John C. , Lapalombella Rosa , Woyach Jennifer A.
Published: April 2023

Supplemental Table 4: Abundance information of top 20 CDR3 sequences and top 10 heavy chains and top 10 light chains (see supplemental Excel file) Supplemental Table 5: DESeq2 normalized counts, log2-fold change, and p-values and adjusted p-values for selected oncogenes, Myc and TCL1A (see supplemental Excel file)
Supplementary Data from Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma
Authors: Lucas Fabienne , Rogers Kerry A. , Harrington Bonnie K. , Pan Alexander , Yu Lianbo , Breitbach Justin , Bundschuh Ralf , Goettl Virginia M. , Hing Zachary A. , Kanga Parviz , Mantel Rose , Sampath Deepa , Smith Lisa L. , Wasmuth Ronni , White Danielle K. , Yan Pearlly , Byrd John C. , Lapalombella Rosa , Woyach Jennifer A.
Published: April 2023

Supplemental Figure 1: Commonly used murine cell surface markers of B-cell development Supplemental Figure 2: Multicolor flow cytometry gating strategy and representative flow plots from a WT spleen sample Supplemental Figure 3: Histopathological assessment of bone marrow aspirates Supplemental Figure 4: Relative changes of mature B-cell subsets in marrow and blood Supplemental Figure 5: Myc and TCL1 expression in CD21-IgM-, CD21-IgM+ and CD19+CD5+ populations Supplemental Figure 6: Characterization of BCR and V gene usage Supplemental Figure 7: B220low/+CD19+CD5+ CLL-like population in recipients of flow-sorted dTG malignancy components Supplemental Figure 8: Immunophenotype of B220+ non-CLL cells in recipients of flow-sorted dTG malignancy components Supplemental Table 1: Fluorophores, concentrations and suppliers of antibodies used to stain murine cells Supplemental Table 2: Low-input RNA-seq post-alignment quality control metrics Supplemental Table 3: Alignment statistics of heavy- and light chain- (lambda and kappa) B-cell receptor (BCR) reads Supplemental Table 6: Characteristics of recipient mice and engrafted diseases after injection of flow-sorted CLL, CD21-IgM- and CD21-IgM+ cells obtained from pooled diseased dTG donor mice (n=3)
Supplementary Table S4 from Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia
Authors: Walker Christopher J. , Kohlschmidt Jessica , Eisfeld Ann-Kathrin , Mrózek Krzysztof , Liyanarachchi Sandya , Song Chi , Nicolet Deedra , Blachly James S. , Bill Marius , Papaioannou Dimitrios , Oakes Christopher C. , Giacopelli Brian , Genutis Luke K. , Maharry Sophia E. , Orwick Shelley , Archer Kellie J. , Powell Bayard L. , Kolitz Jonathan E. , Uy Geoffrey L. , Wang Eunice S. , Carroll Andrew J. , Stone Richard M. , Byrd John C. , de la Chapelle Albert , Bloomfield Clara D.
Published: April 2023

Mutations detected in 425 CN-AML patients
Supplementary Data from Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia
Authors: Walker Christopher J. , Kohlschmidt Jessica , Eisfeld Ann-Kathrin , Mrózek Krzysztof , Liyanarachchi Sandya , Song Chi , Nicolet Deedra , Blachly James S. , Bill Marius , Papaioannou Dimitrios , Oakes Christopher C. , Giacopelli Brian , Genutis Luke K. , Maharry Sophia E. , Orwick Shelley , Archer Kellie J. , Powell Bayard L. , Kolitz Jonathan E. , Uy Geoffrey L. , Wang Eunice S. , Carroll Andrew J. , Stone Richard M. , Byrd John C. , de la Chapelle Albert , Bloomfield Clara D.
Published: April 2023

Supplementary Methods, Supplementary References Supplementary Table S1: Inherited regions of homozygosity in >1% of 1,798 non-leukemic individuals Supplementary Table S2: Acquired uniparental disomies detected in 425 cytogenetically normal AML patients Supplementary Table S3. Associations between recurrent UPDs with pretreatment patient characteristics for patients with cytogenetically normal acute myeloid leukemia Supplementary Table S5. Variant allele fraction of gene mutations that co-occurred with UPDs Supplementary Table S6. Allelic ratio of FLT3 internal tandem duplications that co-occurred with UPDs Supplementary Table S7: Copy number gains and losses in 425 patients with cytogenetically normal acute myeloid leukemia
Supplementary Data 4 from Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms
Authors: Carrillo-Cruz Estrella , García-Lozano José R. , Márquez-Malaver Francisco J. , Sánchez-Guijo Fermín M. , Montero Cuadrado Isabel , Ferra i Coll Christelle , Valcárcel David , López-Godino Oriana , Cuesta Marian , Parody Rocío , López-Corral Lucía , Alcoceba Miguel , Caballero-Velázquez Teresa , Rodríguez-Gil Alfonso , Bejarano-García José A. , Ramos Teresa Lopes , Pérez-Simón José A.
Published: April 2023

Impact of patients VDR polymorphisms on the incidence of overall and moderate-severe chronic GVHD.
Supplementary Tables from TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG)
Authors: Werbrouck Coralie , Evangelista Cláudia C.S. , Lobón-Iglesias María-Jesús , Barret Emilie , Le Teuff Gwénaël , Merlevede Jane , Brusini Romain , Kergrohen Thomas , Mondini Michele , Bolle Stéphanie , Varlet Pascale , Beccaria Kevin , Boddaert Nathalie , Puget Stéphanie , Grill Jacques , Debily Marie-Anne , Castel David
Published: April 2023

Supplementary Tables
Supplementary Figures and Table from IL23-Producing Human Lung Cancer Cells Promote Tumor Growth via Conversion of Innate Lymphoid Cell 1 (ILC1) into ILC3
Authors: Koh Jaemoon , Kim Hye Young , Lee Youngha , Park In Kyu , Kang Chang Hyun , Kim Young Tae , Kim Ji-Eun , Choi Murim , Lee Won-Woo , Jeon Yoon Kyung , Chung Doo Hyun
Published: April 2023

Supplementary Figures and Table
Supplementary Data from A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
Authors: Furman Wayne L. , Federico Sara M. , McCarville Mary Beth , Shulkin Barry L. , Davidoff Andrew M. , Krasin Matthew J. , Sahr Natasha , Sykes April , Wu Jianrong , Brennan Rachel C. , Bishop Michael William , Helmig Sara , Stewart Elizabeth , Navid Fariba , Triplett Brandon , Santana Victor M. , Bahrami Armita , Anthony Gwendolyn , Yu Alice L. , Hank Jacquelyn , Gillies Stephen D. , Sondel Paul M. , Leung Wing H. , Pappo Alberto S.
Published: April 2023

Tables of antibody infusion times and Curie Scores
Supplementary Table S6 from BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas
Authors: Field Matthew G. , Kuznetsov Jeffim N. , Bussies Parker L. , Cai Louie Z. , Alawa Karam A. , Decatur Christina L. , Kurtenbach Stefan , Harbour J. William
Published: April 2023

BAP1KDvsWT_HyperMethDecGE: All significantly hypermethylated probes from hypermethylated/downregulated genes (p < 0.05) with an absolute value (log2(RNA fold change)) > 1 and absolute value (methylation Delta Beta value) > 0.01 in BAP1KDvsWT 92.1 and Mel202 cells. BAP1KDvsWT_HypoMethIncGE: All significantly hypomethylated probes from hypomethylated/upregulated genes (p < 0.05) with an absolute value (log2(RNA fold change)) > 1 and absolute value (methylation Delta Beta value) > 0.01 in BAP1KDvsWT 92.1 and Mel202 cells. BAP1KD_HyperMethDecGE_ChrLoc: Chromosomal loci enriched (FDR < 0.05) for hypermethylated/downregulated genes in BAP1KDvsWT 92.1 and Mel202 cells. BAP1KD_HypoMethIncGE_ChrLoc: Chromosomal loci enriched (FDR < 0.05) for hypomethylated/upregulated genes in BAP1KDvsWT 92.1 and Mel202 cells. BAP1KD_HyperMethDecGE_KEGG: Functional (KEGG and REACTOME) pathways enriched (FDR < 0.05) for hypermethylated/downregulated genes in BAP1KDvsWT 92.1 and Mel202 cells. BAP1KD_HypoMethIncGE_KEGG: Functional (KEGG and REACTOME) pathways enriched (FDR < 0.05) for hypomethylated/upregulated genes in BAP1KDvsWT 92.1 and Mel202 cells. BAP1KD_TCGA_HyperMethDecGE_Gene: All significantly hypermethylated probes (FDR < 0.05) from hypermethylated/downregulated genes shared in common between the shBAP1KD (p < 0.05) and TCGA (FDR < 0.05) datasets. BAP1KD_TCGA_HypoMethIncGE_Gene: All significantly hypomethylated probes (FDR < 0.05) from hypomethylated/upregulated genes shared in common between the shBAP1KD (p < 0.05) and TCGA (FDR < 0.05) datasets.
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Authors: Parada Carolina A. , Osbun Joshua W. , Busald Tina , Karasozen Yigit , Kaur Sumanpreet , Shi Min , Barber Jason , Adidharma Widya , Cimino Patrick J. , Pan Catherine , Gonzalez-Cuyar Luis F. , Rostomily Robert , Born Donald E. , Zhang Jing , Ferreira Manuel
Published: April 2023

Table S4
Supplementary Table S5 from BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas
Authors: Field Matthew G. , Kuznetsov Jeffim N. , Bussies Parker L. , Cai Louie Z. , Alawa Karam A. , Decatur Christina L. , Kurtenbach Stefan , Harbour J. William
Published: April 2023

BAP1KDvsWT_HyperMethyl: All significantly hypermethylated probes (FDR < 0.05) with an absolute value (log2(RNA fold change)) > 1 and absolute value (methylation Delta Beta value) > 0.01 in BAP1KDvsWT 92.1 and Mel202 cells. BAP1KDvsWT_HypoMethyl: All significantly hypomethylated probes (FDR < 0.05) with an absolute value (log2(RNA fold change)) > 1 and absolute value (methylation Delta Beta value) > 0.01 in BAP1KDvsWT 92.1 and Mel202 cells. BAP1KD_HyperMeth_ChrLoc: Chromosomal loci enriched (FDR < 0.05) for top 1000 hypermethylated genes in BAP1KDvsWT 92.1 and Mel202 cells. BAP1KD_HypoMeth_ChrLoc: Chromosomal loci enriched (FDR < 0.05) for top 1000 hypomethylated genes in BAP1KDvsWT 92.1 and Mel202 cells. BAP1KD_HyperMeth_KEGG_REACTOME: Functional (KEGG and REACTOME) pathways enriched (FDR < 0.05) for top 1000 hypermethylated genes in BAP1KDvsWT 92.1 and Mel202 cells. BAP1KD_HypoMeth_KEGG_REACTOME: Functional (KEGG and REACTOME) pathways enriched (FDR < 0.05) for for top 1000 hypomethylated genes in BAP1KDvsWT 92.1 and Mel202 cells.
Supplementary Table S3 from BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas
Authors: Field Matthew G. , Kuznetsov Jeffim N. , Bussies Parker L. , Cai Louie Z. , Alawa Karam A. , Decatur Christina L. , Kurtenbach Stefan , Harbour J. William
Published: April 2023

HyperMethvsDecGE_Cutoffs: All significantly hypermethylated probes from hypermethylated/downregulated genes (FDR < 0.05) with an absolute value (log2(RNA fold change)) > 1 and absolute value (methylation Delta Beta value) > 0.05 in Class 2 uveal melanomas compared to Class 1 uveal melanomas. HypoMethvsIncGE_Cutoffs: All significantly hypomethylated probes from hypomethylated/upregulated genes (FDR < 0.05) with an absolute value (log2(RNA fold change)) > 1 and absolute value (methylation Delta Beta value) > 0.05 in Class 2 uveal melanomas compared to Class 1 uveal melanomas. HyperMethvsDecGE: All significantly hypermethylated probes from hypermethylated/downregulated genes (FDR < 0.05) in Class 2 uveal melanomas compared to Class 1 uveal melanomas. HypoMethvsIncGE: All significantly hypomethylated probes significant hypomethylated/upregulated genes (FDR < 0.05) in Class 2 uveal melanomas compared to Class 1 uveal melanomas.
Supplementary Table S6 from Anagrelide for Gastrointestinal Stromal Tumor
Authors: Pulkka Olli-Pekka , Gebreyohannes Yemarshet K. , Wozniak Agnieszka , Mpindi John-Patrick , Tynninen Olli , Icay Katherine , Cervera Alejandra , Keskitalo Salla , Murumägi Astrid , Kulesskiy Evgeny , Laaksonen Maria , Wennerberg Krister , Varjosalo Markku , Laakkonen Pirjo , Lehtonen Rainer , Hautaniemi Sampsa , Kallioniemi Olli , Schöffski Patrick , Sihto Harri , Joensuu Heikki
Published: April 2023

Supplementary Table S6. The primers used in the quantitative PCR analyses.
Supplementary Table S5 from Anagrelide for Gastrointestinal Stromal Tumor
Authors: Pulkka Olli-Pekka , Gebreyohannes Yemarshet K. , Wozniak Agnieszka , Mpindi John-Patrick , Tynninen Olli , Icay Katherine , Cervera Alejandra , Keskitalo Salla , Murumägi Astrid , Kulesskiy Evgeny , Laaksonen Maria , Wennerberg Krister , Varjosalo Markku , Laakkonen Pirjo , Lehtonen Rainer , Hautaniemi Sampsa , Kallioniemi Olli , Schöffski Patrick , Sihto Harri , Joensuu Heikki
Published: April 2023

Supplementary Table S5. List of genes most affected by anagrelide treatment and protein expression data.
Supplementary Data from Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation
Authors: Kinsella Timothy , Safran Howard , Wiersma Susan , DiPetrillo Thomas , Schumacher Andrew , Rosati Kayla , Vatkevich John , Anderson Lawrence W. , Hill Kimberly D. , Kunos Charles , Collins Jerry M.
Published: April 2023

Supplementary Pharmacokinetic Methods and Analyses
Supplementary Table S2 from Anagrelide for Gastrointestinal Stromal Tumor
Authors: Pulkka Olli-Pekka , Gebreyohannes Yemarshet K. , Wozniak Agnieszka , Mpindi John-Patrick , Tynninen Olli , Icay Katherine , Cervera Alejandra , Keskitalo Salla , Murumägi Astrid , Kulesskiy Evgeny , Laaksonen Maria , Wennerberg Krister , Varjosalo Markku , Laakkonen Pirjo , Lehtonen Rainer , Hautaniemi Sampsa , Kallioniemi Olli , Schöffski Patrick , Sihto Harri , Joensuu Heikki
Published: April 2023

Supplemantary Table S2. KIT and ANO1 expression in 630 human cancers.
Supplementary Data from Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer
Authors: Lohrmann Christian , O'Reilly Eileen M. , O'Donoghue Joseph A. , Pandit-Taskar Neeta , Carrasquillo Jorge A. , Lyashchenko Serge K. , Ruan Shutian , Teng Rebecca , Scholz Wolfgang , Maffuid Paul W. , Lewis Jason S. , Weber Wolfgang A.
Published: April 2023

Supplementary Data
Supplementary Materials and Methods from Anagrelide for Gastrointestinal Stromal Tumor
Authors: Pulkka Olli-Pekka , Gebreyohannes Yemarshet K. , Wozniak Agnieszka , Mpindi John-Patrick , Tynninen Olli , Icay Katherine , Cervera Alejandra , Keskitalo Salla , Murumägi Astrid , Kulesskiy Evgeny , Laaksonen Maria , Wennerberg Krister , Varjosalo Markku , Laakkonen Pirjo , Lehtonen Rainer , Hautaniemi Sampsa , Kallioniemi Olli , Schöffski Patrick , Sihto Harri , Joensuu Heikki
Published: April 2023

Supplementary Materials and Methods
Supplementary Table S1 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Authors: Parmar Kalindi , Kochupurakkal Bose S. , Lazaro Jean-Bernard , Wang Zhigang C. , Palakurthi Sangeetha , Kirschmeier Paul T. , Yang Chunyu , Sambel Larissa A. , Färkkilä Anniina , Reznichenko Elizaveta , Reavis Hunter D. , Dunn Connor E. , Zou Lee , Do Khanh T. , Konstantinopoulos Panagiotis A. , Matulonis Ursula A. , Liu Joyce F. , D'Andrea Alan D. , Shapiro Geoffrey I.
Published: April 2023

Characterization of high-grade serous ovarian cancer models
Supplementary Figure Legends from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Authors: Parmar Kalindi , Kochupurakkal Bose S. , Lazaro Jean-Bernard , Wang Zhigang C. , Palakurthi Sangeetha , Kirschmeier Paul T. , Yang Chunyu , Sambel Larissa A. , Färkkilä Anniina , Reznichenko Elizaveta , Reavis Hunter D. , Dunn Connor E. , Zou Lee , Do Khanh T. , Konstantinopoulos Panagiotis A. , Matulonis Ursula A. , Liu Joyce F. , D'Andrea Alan D. , Shapiro Geoffrey I.
Published: April 2023

Supplementary Figure Legends
Figure S7 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Authors: Parmar Kalindi , Kochupurakkal Bose S. , Lazaro Jean-Bernard , Wang Zhigang C. , Palakurthi Sangeetha , Kirschmeier Paul T. , Yang Chunyu , Sambel Larissa A. , Färkkilä Anniina , Reznichenko Elizaveta , Reavis Hunter D. , Dunn Connor E. , Zou Lee , Do Khanh T. , Konstantinopoulos Panagiotis A. , Matulonis Ursula A. , Liu Joyce F. , D'Andrea Alan D. , Shapiro Geoffrey I.
Published: April 2023

Prexasertib has activity in BRCA1-deficient ovariain cancer cells that have restored replication fork stability and acquired PARP inhibitor resistance
Figure S1 from Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach
Authors: Chang Jason C. , Alex Deepu , Bott Matthew , Tan Kay See , Seshan Venkatraman , Golden Andrew , Sauter Jennifer L. , Buonocore Darren J. , Vanderbilt Chad M. , Gupta Sounak , Desmeules Patrice , Bodd Francis M. , Riely Gregory J. , Rusch Valerie W. , Jones David R. , Arcila Maria E. , Travis William D. , Ladanyi Marc , Rekhtman Natasha
Published: April 2023

Supplemental Figure 1
Supplemental Figure 3 from B7-H3 Expression in Merkel Cell Carcinoma–Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density
Authors: Aung Phyu P. , Parra Edwin Roger , Barua Souptik , Sui Dawen , Ning Jing , Mino Barbara , Ledesma Debora Alejandra , Curry Jonathan L. , Nagarajan Priyadharsini , Torres-Cabala Carlos A. , Efstathiou Eleni , Hoang Anh G. , Wong Michael K. , Wargo Jennifer A. , Lazar Alexander J. , Rao Arvind , Prieto Victor G. , Wistuba Ignacio , Tetzlaff Michael T.
Published: April 2023

Supplemental Figure 3. Correlation between B7-H3/CD31 G-function co-localization index in MCPyV-negative MCCs. Plots showing the correlation B7-H3/CD31 G-function co-localization index for each primary MCPyV-negative MCC plotted against the frequency of associated malignancies (A) and lymphovascular invasion (B). G-function calculated according to a 1 pixel (1.57 ï�­m) radius.
Supplemental Figure 1 from B7-H3 Expression in Merkel Cell Carcinoma–Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density
Authors: Aung Phyu P. , Parra Edwin Roger , Barua Souptik , Sui Dawen , Ning Jing , Mino Barbara , Ledesma Debora Alejandra , Curry Jonathan L. , Nagarajan Priyadharsini , Torres-Cabala Carlos A. , Efstathiou Eleni , Hoang Anh G. , Wong Michael K. , Wargo Jennifer A. , Lazar Alexander J. , Rao Arvind , Prieto Victor G. , Wistuba Ignacio , Tetzlaff Michael T.
Published: April 2023

Supplemental Figure 1. Dynamic range of co-localized expression of CD31 and B7-H3 in primary Merkel cell carcinoma. Each CD31+ and B7-H3+ cell centroid was tabulated as a series of (X, Y) coordinates (cell centroids). The frequency of their respective overlap for each of the 52 primary MCCs was calculated within a given distance as indicated: blue boxes show G-function colocalization index applying a 1 pixel (1.57 ï�­m) minimum distance of overlapped expression as our cutoff, and green boxes show G-function colocalization index applying a 2 pixel (3.14 ï�­m) minimum distance of overlapped expression as our cutoff.
Supplementary Figures from Molecular Characterization of Neuroendocrine-like Bladder Cancer
Authors: Batista da Costa José , Gibb Ewan A. , Bivalacqua Trinity J. , Liu Yang , Oo Htoo Zarni , Miyamoto David T. , Alshalalfa Mohammed , Davicioni Elai , Wright Jonathan , Dall’Era Marc A. , Douglas James , Boormans Joost L. , Van der Heijden Michiel S. , Wu Chin-Lee , van Rhijn Bas W.G. , Gupta Shilpa , Grivas Petros , Mouw Kent W. , Murugan Paari , Fazli Ladan , Ra Seong , Konety Badrinath R. , Seiler Roland , Daneshmand Siamak , Mian Omar Y. , Efstathiou Jason A. , Lotan Yair , Black Peter C.
Published: April 2023

Supplemental figures and box plots
Supplementary Data from Molecular Characterization of Neuroendocrine-like Bladder Cancer
Authors: Batista da Costa José , Gibb Ewan A. , Bivalacqua Trinity J. , Liu Yang , Oo Htoo Zarni , Miyamoto David T. , Alshalalfa Mohammed , Davicioni Elai , Wright Jonathan , Dall’Era Marc A. , Douglas James , Boormans Joost L. , Van der Heijden Michiel S. , Wu Chin-Lee , van Rhijn Bas W.G. , Gupta Shilpa , Grivas Petros , Mouw Kent W. , Murugan Paari , Fazli Ladan , Ra Seong , Konety Badrinath R. , Seiler Roland , Daneshmand Siamak , Mian Omar Y. , Efstathiou Jason A. , Lotan Yair , Black Peter C.
Published: April 2023

Supplemental Tables
Supplementary Data from TRIB3 Stabilizes High TWIST1 Expression to Promote Rapid APL Progression and ATRA Resistance
Authors: Lin Jian , Zhang Wu , Niu Li-Ting , Zhu Yong-Mei , Weng Xiang-Qin , Sheng Yan , Zhu Jiang , Xu Jie
Published: April 2023

Supplementary Table 1. Characteristics of the 64 AML patients at diagnosis.
Supplementary Data from TRIB3 Stabilizes High TWIST1 Expression to Promote Rapid APL Progression and ATRA Resistance
Authors: Lin Jian , Zhang Wu , Niu Li-Ting , Zhu Yong-Mei , Weng Xiang-Qin , Sheng Yan , Zhu Jiang , Xu Jie
Published: April 2023

Supplementary Figure 1. TWIST1 was highly expressed in APL cells. Supplementary Figure 2. High TWIST1 expression promotes APL progression. Supplementary Figure 3. TRIB3 interacts with TWIST1 in APL cells. Supplementary Figure 4. TRIB3 inhibition promotes TWIST1 degradation and reverses resistance to ATRA therapy. Supplementary Figure 5. The WR domain of TWIST1 is required for the binging of TWIST1/TRIB3 complex and TWIST1 stabilization. Supplementary Figure 6. Competitive inhibition of the TRIB3/TWIST1 interaction impairs rapid progression during the early death of APL.